These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 9294779

  • 1. Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: reversal after mixing with aprotinin.
    Lunetta M, Di Mauro M, Le Moli R.
    J Endocrinol Invest; 1997 Jun; 20(6):331-4. PubMed ID: 9294779
    [Abstract] [Full Text] [Related]

  • 2. Effect of octreotide on blood glucose and counterregulatory hormones in insulin-dependent diabetic patients: the role of dose and route of administration.
    Lunetta M, De Mauro M, Le Moli R, Nicoletti F.
    Eur J Clin Pharmacol; 1996 Jun; 51(2):139-44. PubMed ID: 8911878
    [Abstract] [Full Text] [Related]

  • 3. Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients.
    Bruttomesso D, Fongher C, Silvestri B, Barberio S, Marescotti MC, Iori E, Valerio A, Crazzolara D, Pianta A, Tiengo A, Del Prato S.
    Diabetes Res Clin Pract; 2001 Feb; 51(2):97-105. PubMed ID: 11165689
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes.
    Osei K, O'Dorisio TM, Malarkey WB, Cataland S.
    J Lab Clin Med; 1991 Jul; 118(1):56-64. PubMed ID: 2066644
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The use of continuous subcutaneous octreotide infusion in brittle type 1 diabetic patients.
    Bello F, Falko JM, O'Dorisio TM, Osei K.
    Diabet Med; 1991 May; 8(4):385-7. PubMed ID: 1830262
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of octreotide on growth hormone, IGF-I, IGFBP-3, glucagon, cortisol and epinephrine response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients.
    Lunetta M, Di Mauro M, Le Moli R, Nicoletti F.
    Diabetes Metab; 1997 Dec; 23(6):524-7. PubMed ID: 9496559
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C, Fatti L, Camboni MG, Porcu L, Danesi L, Delitala G, Cavagnini F.
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [Abstract] [Full Text] [Related]

  • 18. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
    Hadjidakis DJ, Halvatsiotis PG, Ioannou YJ, Mavrokefalos PJ, Raptis SA.
    Diabetes Res Clin Pract; 1988 Jul 13; 5(2):91-8. PubMed ID: 2901329
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.